ibrutinib monotherapy in wm: long-term follow-up data
Published 1 year ago • 72 plays • Length 2:04Download video MP4
Download video MP3
Similar videos
-
1:24
the long-term safety and efficacy of ibrutinib monotherapy in patients with previously-treated wm
-
3:03
long-term follow-up of ibrutinib in waldenström's macroglobulinemia
-
1:29
insights into the uses of ibrutinib for patients with waldenström’s macroglobulinemia
-
1:27
ibrutinib therapy for waldenström’s macroglobulinemia: real-world experiences in the uk
-
1:44
the efficacy of zanubrutinib versus ibrutinib in patients with wm harboring various mutations
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
3:08
recent updates on tp53 mutation in cll
-
4:14
waldenström’s macroglobulinaemia and active monitoring: kate's story
-
1:34
innovate study update: long-term pfs in wm
-
2:14
single agent ibrutinib produces long-term disease control in waldenström’s: the pivotal trial
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl
-
2:23
waldenström’s: predicting ibrutinib responses
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
1:19
zanubrutinib monotherapy in r/r indolent nhl
-
1:54
nivolumab ibrutinib for patients with richter’s transformation
-
3:28
emerging therapies for wm: acalabrutinib and zanubrutinib
-
2:07
efficacy of ibrutinib in the treatment of cll patients with del(17p) and tp53 mutation
-
3:16
aspen: zanubrutinib vs ibrutinib in waldenström's macroglobulinemia
-
1:35
phase i/ii bruin update: efficacy of pirtobrutinib in r/r waldenström's macroglobulinemia
-
1:17
ibrutinib & chemotherapy (teddi-r) in the treatment of secondary cns lymphoma
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:28
phase i study of pevonedistat and ibrutinib in r/r b-nhl